TriSalus Life Sciences, Inc. Common Stock (TLSI)

Price$3.67

Value ScoreD

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-47.18%

Price vs S&P 500 (4W)-27.30%

VGM Score39.63

Market Capitalization$209.43M

All Metrics

Book Value / Share (Quarterly)$0.21

P/TBV (Annual)16.11x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.33

Price vs S&P 500 (YTD)-62.08%

Gross Margin (TTM)85.07%

Net Profit Margin (TTM)-60.85%

EPS (TTM)$-0.68

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-0.68

EPS (Annual)$-1.04

ROI (Annual)71.03%

Gross Margin (Annual)84.57%

Cash / Share (Quarterly)$0.92

Revenue Growth QoQ (YoY)-2.92%

ROA (Last FY)-111.03%

Revenue Growth TTM (YoY)39.64%

EBITD / Share (TTM)$-0.63

Operating Margin (TTM)-62.45%

Cash Flow / Share (Annual)$-0.38

P/B Ratio16.35x

P/B Ratio (Quarterly)19.18x

Net Income / Employee (Annual)$-384,600

EV / Revenue (TTM)4.14x

Net Interest Coverage (TTM)-6.86x

ROA (TTM)-59.35%

EPS Incl Extra (Annual)$-1.04

Current Ratio (Annual)2.80x

Quick Ratio (Quarterly)5.24x

3-Month Avg Trading Volume0.30M

52-Week Price Return-37.77%

EV / Free Cash Flow (Annual)19.22x

Revenue / Employee (TTM)$440,000

Tangible BV / Share (Quarterly)$0.28

P/S Ratio (Annual)4.64x

Asset Turnover (Annual)1.28x

52-Week High$7.95

EPS Excl Extra (Annual)$-1.04

26-Week Price Return-31.25%

Quick Ratio (Annual)2.35x

13-Week Price Return-36.62%

Total Debt / Equity (Annual)0.20x

Current Ratio (Quarterly)5.78x

Enterprise Value$185.96M

Asset Turnover (TTM)0.98x

Revenue / Employee (Annual)$442,700

Pretax Margin (Annual)-86.86%

Cash / Share (Annual)$0.41

3-Month Return Std Dev100.06%

Net Income / Employee (TTM)$-267,800

ROE (Last FY)85.23%

Net Interest Coverage (Annual)-4.33x

EPS Basic Excl Extra (Annual)$-1.04

Receivables Turnover (TTM)8.41x

EV / Free Cash Flow (TTM)46.64x

Total Debt / Equity (Quarterly)2.58x

EPS Incl Extra (TTM)$-0.68

ROI (TTM)3.35%

P/S Ratio (TTM)4.67x

Revenue / Share (Annual)$1.19

Tangible BV / Share (Annual)$0.80

Price vs S&P 500 (52W)-65.98%

Year-to-Date Return-51.15%

5-Day Price Return4.60%

EPS Normalized (Annual)$-1.04

ROA (5Y Avg)-89.67%

Net Profit Margin (Annual)-86.88%

Month-to-Date Return-21.06%

Cash Flow / Share (TTM)$0.09

EBITD / Share (Annual)$-0.69

Operating Margin (Annual)-59.68%

LT Debt / Equity (Annual)0.20x

LT Debt / Equity (Quarterly)2.58x

EPS Basic Excl Extra (TTM)$-0.68

P/TBV (Quarterly)17.74x

P/B Ratio (Annual)5.02x

Inventory Turnover (TTM)1.69x

Pretax Margin (TTM)-60.84%

Book Value / Share (Annual)$0.80

Price vs S&P 500 (13W)-46.36%

Beta0.46x

Revenue / Share (TTM)$0.86

ROE (TTM)12.02%

52-Week Low$2.20

vGradeD

gGradeC

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 260.03est. -0.16

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.15

4.09

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
TLSITriSalus Life Sciences, Inc. Common Stock	D	C	D	$3.67
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics for difficult-to-treat hepatocellular and pancreatic cancers. The company commercializes PEDD infusion systems through its TriNav platform with SmartValve technology, while advancing the investigational agent nelitolimod (SD-101) to enhance immune response in liver and pancreatic cancer patients.